Cardiac compromise due to AL amyloidosis: Dissimilarity as an attribute. Report of 3 cases
DOI:
https://doi.org/10.17533/udea.iatreia.65Keywords:
amyloid, amyloidosis, heart failure, restrictive cardiomyopathy, syncopeAbstract
AL amyloidosis (formerly called primary amyloidosis) is a rare systemic entity, with an unknown incidence in the world, which can develop heart involvement in almost half of patients, leading to restrictive cardiomyopathy by amyloid tissue deposit. We present 3 cases of patients who consulted for acute heart failure and syncope, in which the diagnosis of AL amyloidosis was finally confirmed. We conclude with a brief review of the literature, emphasizing clinical elements for an early diagnosis.
Downloads
References
(1) Baker KR, Rice L. The Amyloidoses: Clinical Features, Diagnosis and Treatment. Methodist Debakey Cardiovasc J. 2012;8(3):3-7. DOI 10.14797/mdcj-8-3-3.
(2) Gertz MA, Lacy MQ, Dispenzieri A. Amyloidosis. Hematol Oncol Clin North Am. 1999;13(6):1211-1233,ix. DOI 10.1016/S0889-8588(05)70122-2.
(3) Dubrey SW, Cha K, Anderson J, Chamarthi B, Reisinger J, Skinner M, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM. 1998;91(2):141-157. DOI 10.1093/qjmed/91.2.141.
(4) Katzmann JA, Abraham RS, Dispenzieri A, Lust JA, Kyle RA. Diagnostic Performance of Quantitative κ and λ Free Light Chain Assays in Clinical Practice. Clin Chem. 2005;51(5):878-881. DOI 10.1373/clinchem.2004.046870.
(5) Madan S, Dispenzieri A, Lacy MQ, Buadi F, Hayman SR, Zeldenrust SR et al. Clinical Features and Treatment Response of Light Chain (AL) Amyloidosis Diagnosed in Patients with Previous Diagnosis of Multiple Myeloma. Mayo Clin Proc. 2010;85(3):232-238. DOI 10.4065/mcp.2009.0547.
(6) Falk RH. Diagnosis and Management of the Cardiac Amyloidoses. Circulation. 2005;112(13):2047-2060. DOI 10.1161/CIRCULATIONAHA.104.489187.
(7) Feng D, Edwards WD, Oh JK, Chandrasekaran K, Grogan M, Martinez MW et al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation. 2007;116(21):2420-2426. DOI 10.1161/CIRCULATIONAHA.107.697763.
(8) Mohty D, Damy T, Cosnay P, Echahidi N, Casset-Senon D, Virot P et al. Cardiac amyloidosis: updates in diagnosis and management. Arch Cardiovasc Dis. 2013;106(10):528-540. DOI 10.1016/j.acvd.2013.06.051.
(9) Desai HV, Aronow WS, Peterson SJ, Frishman WH. Cardiac Amyloidosis: Approaches to Diagnosis and Management. Cardiol Rev. 2010;18(1):1-11. DOI 10.1097/CRD.0b013e3181bdba8f.
(10) García-Pavía P, Tomé-Esteban MT, Rapezzi C. Amiloidosis. También una enfermedad del corazón. Revista Española de Cardiología. 2011;64(9):797-808. DOI 10.1016/j.recesp.2011.05.003.
(11) Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I et al. Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation. 2005;111(2):186-193. DOI 10.1161/01.CIR.0000152819.97857.9D.
(12) Pellikka PA, Holmes DR, Edwards WD, Nishimura RA, Tajik AJ, Kyle RA. Endomyocardial Biopsy in 30 Patients with Primary Amyloidosis and Suspected Cardiac Involvement. Arch Intern Med. 1988;148(3):662-666. DOI 10.1001/archinte.1988.00380030168027.
(13) Ardehali H, Qasim A, Cappola T, Howard D, Hruban R, Hare JM et al. Endomyocardial biopsy plays a role in diagnosing patients with unexplained cardiomyopathy. Am Heart J. 2004;147(5):919-923. DOI 10.1016/j.ahj.2003.09.020.
(14) Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD. Updates in cardiac amyloidosis: a review. J Am Heart Assoc. 2012;1(2):e000364. DOI 10.1161/JAHA.111.000364.
(15) Wechalekar AD, Hawkins PN, Gillmore JD. Perspectives in treatment of AL amyloidosis. Br J Haematol. 2008;140(4):365-377. DOI 10.1111/j.1365-2141.2007.06936.x.
(16) Mahmood S, Palladini G, Sanchorawala V, Wechalekar A. Update on treatment of light chain amyloidosis. Haematologica. 2014;99(2):209-221. DOI 10.3324/haematol.2013.087619.
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Universidad de Antioquia
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Papers published in the journal are available for use under the Creative Commons license, specifically Attribution-NonCommercial-ShareAlike 4.0 International.
The papers must be unpublished and sent exclusively to the Journal Iatreia; the author uploading the contribution is required to submit two fully completed formats: article submission and authorship responsibility.
